• Laurence Boudou, Mathieu Baconnier, Jean-Yves Blay, Catherine Lombard-Bohas, and Philippe A Cassier.
• Unité de Jour d'Oncologie Médicale Multidisciplinaire, Hôpital Edouard Herriot, Lyon, France.
• Expert Rev Anticancer Ther. 2009 Jun 1; 9 (6): 727-37.

AbstractTrabectedin is a new marine-derived compound that binds the DNA minor groove and interacts with proteins of the DNA-repair machinery. Trabectedin has shown promising single-agent activity in pretreated patients with soft-tissue sarcoma (STS) and ovarian and breast cancer; combination with various other chemotherapeutic drugs is feasible. Toxicities are mainly hematological and hepatic, with grade 3-4 neutropenia and thrombocytopenia observed in approximately 50 and 20% of patients, respectively, and grade 3-4 elevation of liver transaminases observed in 35-50% of patients treated with trabectedin. Trabectedin obtained regulatory approval by the EMEA and in other countries for the treatment of STS patients after failure of all available standard-of-care chemotherapy. Current research focuses on the identification of predictive factors for patients treated with trabectedin as well as the development of other combinations.

38 keywords...

hide…